Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COGT 
Cogent Biosciences Inc (COGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: COGT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.67
1 Year Target Price $20.67
| 5 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.73% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.29B USD | Price to earnings Ratio - | 1Y Target Price 20.67 |
Price to earnings Ratio - | 1Y Target Price 20.67 | ||
Volume (30-day avg) 12 | Beta 0.3 | 52 Weeks Range 3.72 - 16.99 | Updated Date 10/18/2025 |
52 Weeks Range 3.72 - 16.99 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -53.15% | Return on Equity (TTM) -107.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1991311741 | Price to Sales(TTM) 1320.63 |
Enterprise Value 1991311741 | Price to Sales(TTM) 1320.63 | ||
Enterprise Value to Revenue 925.41 | Enterprise Value to EBITDA -3.89 | Shares Outstanding 139700796 | Shares Floating 102748660 |
Shares Outstanding 139700796 | Shares Floating 102748660 | ||
Percent Insiders 0.04 | Percent Institutions 105.91 |
Upturn AI SWOT
Cogent Biosciences Inc
Company Overview
History and Background
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Originally founded in 2014 as Forma Therapeutics, the company transitioned to Cogent Biosciences in 2020 to reflect its new focus.
Core Business Areas
- Precision Oncology: Focuses on developing therapies that target specific genetic mutations in cancer. Lead candidate is bezuclastinib, a selective tyrosine kinase inhibitor.
Leadership and Structure
Andrew Robbins is the CEO. The company has a typical biotechnology organizational structure, with departments for research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Bezuclastinib: A selective tyrosine kinase inhibitor targeting KIT D816V. Being evaluated for Advanced Systemic Mastocytosis (AdvSM) and Gastrointestinal Stromal Tumors (GIST). It's currently in clinical trials. Market share is not applicable as it is not yet approved. Competitors include Blueprint Medicines with AYVAKITu00ae (avapritinib).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and innovative, characterized by intense research and development, regulatory hurdles, and long development timelines. The oncology market is growing rapidly due to advancements in personalized medicine.
Positioning
Cogent Biosciences is positioned as a precision oncology company targeting specific genetic mutations with its lead candidate, bezuclastinib. Their competitive advantage lies in the selectivity of their drug and its potential to address unmet needs in AdvSM and GIST.
Total Addressable Market (TAM)
The TAM for Advanced Systemic Mastocytosis and GIST is significant. The market is estimated to be several billion dollars annually. Cogent is positioned to capture a portion of this market with successful clinical trial outcomes and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Selective tyrosine kinase inhibitor (bezuclastinib)
- Focus on genetically defined diseases
- Experienced management team
- Promising clinical trial results for lead candidate
Weaknesses
- Reliance on single lead candidate
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Not yet commercially selling products
Opportunities
- Expansion of indications for bezuclastinib
- Development of additional precision oncology therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial data
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BLUP
- ARRY
- GILD
- MRTX
Competitive Landscape
Cogent is a smaller player compared to established pharmaceutical companies. Cogent differentiates itself through the selectivity of bezuclastinib and its focus on specific genetic mutations. The company is well behind the larger cap companies, because it does not have any currently approved drugs generating revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of the clinical pipeline and expansion of research programs.
Future Projections: Future growth is contingent on the success of bezuclastinib in clinical trials and its subsequent commercialization. Analyst estimates are based on projected market share and pricing.
Recent Initiatives: Recent initiatives include enrolling patients in the bezuclastinib clinical trials and exploring potential partnerships.
Summary
Cogent Biosciences is a clinical-stage biotechnology company focused on precision oncology. Their lead candidate, bezuclastinib, shows promise in treating genetically defined diseases like Advanced Systemic Mastocytosis and GIST. The company's success hinges on the positive outcomes of its clinical trials. They will face challenges with regulatory hurdles and competition from larger players. A strong cash position will be crucial for the next few years.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and based on publicly available data. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cogent Biosciences Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-29 | President, CEO & Director Mr. Andrew R. Robbins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 205 | Website https://www.cogentbio.com |
Full time employees 205 | Website https://www.cogentbio.com | ||
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.